Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma

Welsh, EJ; Cates, CJ (2010) Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. COCHRANE DATABASE OF SYSTEMATIC REVIEWS (9). pp. 1-54. ISSN 1469-493X
SGUL Authors: Cates, Christopher Joseph Welsh, Emma Jane

["document_typename_application/pdf; charset=binary" not defined] Published Version
Download (718kB) | Preview


Background Formoterol is a long-acting beta(2)-agonist but because it has a fast onset of action it can also be used as a relief medication. Objectives To asses the efficacy and safety of formoterol as reliever therapy in comparison to short-acting beta(2)-agonists in adults and children with asthma. Search strategy We searched the Cochrane Airways Group Specialised Register and websites of clinical trial registers (for unpublished trial data), and we checked the Food and Drug Administration (FDA) submissions in relation to formoterol. The date of the most recent search was February 2010. Selection criteria Randomised, parallel-arm trials of at least 12 weeks duration in patients of any age and severity of asthma. Studies randomised patients to any dose of as-needed formoterol versus short-acting beta(2)-agonist. Concomitant use of inhaled corticosteroids or other maintenance medication was allowed, as long as this was not part of the randomised treatment regimen. Data collection and analysis Two authors independently selected trials for inclusion in the review. Outcome data were extracted by one author and checked by the second author. We sought unpublished data on primary outcomes. Main results This review includes eight studies conducted in 22,604 participants (mostly adults). Six studies compared formoterol as-needed to terbutaline whilst two studies compared formoterol with salbutamol as-needed. Background maintenance therapy varied across the trials. Asthma exacerbations and serious adverse events showed a direction of treatment effect favouring formoterol, of which one outcome reached statistical significance (exacerbations requiring a course of oral corticosteroids). In patients on short-acting beta(2)-agonists, 117 people out of 1000 had exacerbations requiring oral corticosteroids over 30 weeks, compared to 101 (95% CI 93 to 108) out of 1000 for patients on formoterol as-needed. In patients on maintenance inhaled corticosteroids there were also significantly fewer exacerbations requiring a course of oral corticosteroids on formoterol as-needed (Peto OR 0.75; 95% CI 0.62 to 0.91). There was one death per 1000 people on formoterol or on short-acting beta(2)-agonists. Authors' conclusions In adults, formoterol was similar to short-acting beta(2)-agonists when used as a reliever, and showed a reduction in the number of exacerbations requiring a course of oral corticosteroids. Clinicians should weigh the relatively modest benefits of formoterol as-needed against the benefits of single inhaler therapy and the potential danger of long-term use of long-acting beta(2)-agonists in some patients. We did not find evidence to recommend changes to guidelines that suggest that long-acting beta(2)-agonists should be given only to patients already taking inhaled corticosteroids.There was insufficient information reported from children in the included trials to come to any conclusion on the safety or efficacy of formoterol as relief medication for children with asthma.

Item Type: Article
Additional Information: This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2010, Issue 9. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review. Welsh EJ, Cates CJ. Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD008418. DOI: 10.1002/14651858.CD008418.pub2.
Keywords: Adult, Age Factors, Albuterol, Asthma, Bronchodilator Agents, Budesonide, Child, Cromolyn Sodium, Ethanolamines, Humans, Nedocromil, Randomized Controlled Trials as Topic, Terbutaline, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, INHALED CORTICOSTEROIDS, COST-EFFECTIVENESS, PERSISTENT ASTHMA, RANDOMIZED-TRIAL, TERBUTALINE, BUDESONIDE, COMBINATION, MODERATE, THERAPY, SAFETY
SGUL Research Institute / Research Centre: Academic Structure > Population Health Research Institute (INPH)
ISSN: 1469-493X
Related URLs:
8 September 2010Published
Web of Science ID: WOS:000281629700036
Publisher's version:

Actions (login required)

Edit Item Edit Item